Abeona Therapeutics (NASDAQ:ABEO) on Wednesday reported financial results for the full year ended December 31, 2025, and provided operational updates centered on the commercial launch of its lead gene therapy ZEVASKYN.
X4 Pharmaceuticals (NASDAQ:XFOR) reported its fourth-quarter and full-year 2025 financial results on March 17, 2026, marking a year of transition from a clinical-stage entity to a commercial-revenue-generating firm.
Victory Capital Holdings (NASDAQ:VCTR) increased the pressure on Janus Henderson Group (NYSE:JHG) today, submitting an enhanced acquisition proposal to the company’s Special Committee.
GDS Holdings (NASDAQ:GDS) reported audited financial results for the fourth quarter and full year ended December 31, 2025, demonstrating resilient growth in its hyperscale data center operations.
Steel Dynamics (NASDAQ:STLD) provided a bullish outlook for the first quarter of 2026, signaling a significant acceleration in profitability compared to both the previous quarter and the prior year.
Pfizer (NYSE:PFE) reported a significant clinical milestone in its oncology pipeline today, announcing that the Phase 2 FOURLIGHT-1 study of atirmociclib met its primary endpoint.
Citi Trends (NASDAQ:CTRN) reported a robust recovery for the fourth quarter ended January 31, 2026, marking a pivotal turn for the off-price retailer.
PSQ Holdings (NYSE:PSQH), the operator of the PublicSquare marketplace and its associated payments infrastructure, released its fourth-quarter and full-year 2025 financial results on March 17, 2026.
Value Line (NASDAQ:VALU) reported financial results for its fiscal third quarter ended January 31, 2026, posting a net income of $5.9 million.
BioCardia (NASDAQ:BCDA) announced on Tuesday that the U.S. Food and Drug Administration has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter.
AtaiBeckley (NASDAQ:ATAI) announced on Tuesday that results from a Phase 2a cohort evaluating BPL-003, its proprietary intranasal formulation of 5-MeO-DMT, have been published in the Journal of Psychopharmacology.
Greenwich LifeSciences (NASDAQ:GLSI) released a preliminary update from its ongoing Phase III FLAMINGO-01 clinical trial, which evaluates the efficacy of GP2, an immunotherapy designed to prevent breast cancer recurrences.
